ASCO 2012
Analyst Briefing

JUNE 3, 2012

Pfizer Oncology

Forward Looking Statements

- Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements.
- The factors that could cause actual results to differ are discussed in Pfizer's 2011 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.
- These reports are available on our website at www.pfizer.com in the "Investors—SEC Filings" section.

Pfizer Oncology Today

Mace Rothenberg, MD

Senior Vice President of Clinical Development and Medical Affairs

Pfizer Oncology

Pfizer Oncology: Growing the Franchise through Precision Medicine and Focused Execution

2008-2009

Mature Product Line

Formation of Oncology Business Unit

SUTENT sunitinib malate

AROMASIN exemestane tablets

CAMPTOSAR irinotecan HCl injection

3 late stage compounds

Acquisition of Wyeth adds Torisel and 2 late stage investigational agents

2012

Diversified Early Pipeline

PD 0332991
CDK 4/6 inhibitor

PF 04691502 oral
PI3K/mTOR

PF 05212384 IV
PI3K/mTOR

PF 04449913
SMO inhibitor

PF 05082566
4-1BB

PF 03446962
ALK – 1 mAb

PF 03084014
Gamma secretase inhibitor

PF 04856884 (CVX-060)
ANG 2

PF 04605412
A5/β1mAb

Growing Late Stage Portfolio

Dacomitinib
Pan-HER inhibitor

Inotuzumab Ozogamicin
Antibody-drug conjugate targeting CD22

Bosutinib Regulatory Filings Accepted in U.S. and EU

Three Launches in 8 Months

INLYTA (axitinib) tablets

XALKORI CRIZOTINIB

SUTENT sunitinib malate

(Pancreatic NET)

Growing Product Line

SUTENT sunitinib malate

TORISEL (temsirolimus) injection

INLYTA (axitinib) tablets

XALKORI CRIZOTINIB

Pfizer Oncology

Key Themes for Pfizer Oncology at ASCO

RCC	Expanding RCC leadership; Providing more options for patients	• Updated INLYTA 2nd-line data; association btwn BP and outcomes in 1st-line • Pooled SUTENT efficacy and tolerability data
LUNG	Using genomic data to inform drug development and treatment selection	• 1st report of crizotinib in ROS1+ NSCLC • 1st report of dacomitinib in EGFR mutant NSCLC
HEME	Promising molecules in all stages of development	• 30-month data on 1st-line bosutinib in CML • Inotuzumab Phase 2 IIR in ALL • 1st report of crizotinib in pediatric ALCL
EARLY DEV	Encouraging clinical data from multiple, first-in-class compounds	• Phase 2 IIR data on CDK 4,6 inhibitor (PD-0332991) in liposarcoma • Phase 1 data on anti ALK-1 monoclonal antibody (PF 03446962) in solid tumors

Pfizer Oncology

RCC – Renal Cell Carcinoma
NSCLC - Non-small Cell Lung Cancer
ALL – Acute Lymphocytic Leukemia
IIR – Investigator Initiated Research
ALCL - Anaplastic Large-Cell Lymphoma
CML – Chronic Myeloid Leukemia

At the Forefront of RCC Treatment Innovation

As the **global leader** in the treatment of advanced kidney cancer, Pfizer has **transformed the treatment paradigm** by providing therapeutic options with varying MOAs for a **broad spectrum of patients**

SUTENT® sunitinib malate	TORISEL® (temsirolimus) injection	INLYTA® (axitinib) tablets (U.S. & Switzerland)
Oral Therapy	**IV Therapy**	**Oral Therapy**
1st-line SOC for favorable and intermediate risk	**Only mTOR inhibitor approved in the 1st-line setting**	**2nd-line after failure of one prior systemic therapy**
First treatment to achieve median OS beyond 2 years	**Only therapy to show a significant improvement in OS for poor risk patients**	**First therapy with pivotal data proving PFS benefit in treatment-refractory patients vs. another targeted agent**

Pfizer Oncology

MOA - Mechanisms of Action
SOC - Standard of Care

OS - Overall Survival
PFS - Progression Free Survival

Updated INLYTA Data Confirm Efficacy in Second Line; Strong U.S. Launch and Filings Under Review Globally

Updated cytokine subgroup analysis from the AXIS 1032 study is generally consistent with previously presented data

Progression-free Survival

(IRC Assessment)



IRC = Independent Review Committee

IN THE U.S.

Now Available

- Launched February 2012 ~ 10 days after FDA approval
- More than 1,200 prescriptions written since launch
- Strong initial demand, meeting expectations
- Positive oncologist feedback

GLOBALLY

Global Regulatory Filings Submitted

- Approved in Switzerland April 2012
- EU CHMP positive opinion received May 2012
- Applications under review in Australia, Canada, Japan, Taiwan, Brazil, Korea, Russia, & Columbia

Pfizer Oncology

Preliminary 1st-line Data* Presented at ASCO; Anticipating Phase 3 1st-Line Data Soon

1st-line mRCC (Study 1046)

- ORR greater than 40%
- mPFS of greater than one year

	Total[a] (N=213)	Arm C Not eligible for dose titration (n=91)	Arms A + B Eligible for dose titration (n=112)
mPFS, mo (95% CI)[b]	14.5 (11.5, 17.4)	16.4 (11.0, 19.0)	14.5 (11.0, 19.3)
ORR (95% CI)[b]	48% (41%, 55%)	59% (49%, 70%)	43% (34%, 53%)

[a] Includes 10 patients who discontinued study treatment prior to decision for dose titration
[b] As of April 30, 2012

Pfizer Oncology

*Still blinded

Xalkori and the Value of Genomic Information in Treatment Selection for NSCLC

XALKORI CAPSULES CRIZOTINIB

Prescriptions written by **>800** physicians in **48** states

Four-fold increase in ALK testing in the U.S. since XALKORI launch

> *"The NCCN panel recommends that all patients with adenocarcinoma be tested for the EGFR mutation [and] ALK gene rearrangement."*

Oncogenic Drivers in NSCLC



~53% Of NSCLC Patients Have A Genetic Mutation Driving Their Cancer

Research into the underlying **genetic drivers** of cancer is leading to a **paradigm shift** in the way **lung cancer is treated**

Pfizer Oncology

ROS1: Another Genomically-Defined Subset of NSCLC Sensitive to Xalkori

Registration Data in ALK+ NSCLC



2012 ASCO Data in ROS1+ NSCLC



Ongoing early and late stage studies continue to evaluate the activity of XALKORI across different **patient populations, tumor types and molecular subsets**

Pfizer Oncology

Dacomitinib Activity in EGFR Mutant 1st-Line NSCLC; Evaluation in Multiple Lines of Therapy

First Phase 2 Data in 1st-line NSCLC (Study 1017)

- **Objective response rate: 74%**
- **Median PFS: 17 months**
- **Oral, once-daily, pan-HER inhibitor**
- **Targets multiple receptors** on the HER pathway



Two Ongoing Phase 3 Trials in Non-Small Cell Lung Cancer



Robust Hematology Pipeline with Multiple Agents

Bosutinib Regulatory Status

- **In January 2012, the U.S. FDA accepted bosutinib**
  for standard review as a treatment option for adult patients with previously treated Ph+ CML

- **In August 2011, the EMA accepted bosutinib**
  for review as a treatment for adult patients with newly diagnosed Ph+ CML in the chronic phase

Inotuzumab Ozogamicin (IO)
INO-VATE Phase 3 Clinical Trials



Hematologic malignancies represent the 5th most commonly occurring cancers and the 2nd leading cause of cancer death worldwide

Pfizer Oncology

NHL – Non Hodgkin Lymphoma
CML – Chronic Myeloid Leukemia
ALL – Acute Lymphocytic Leukemia

Inotuzumab: Promising Phase 2 IIR Data in ALL

- Confirmation of activity of inotuzumab in refractory-relapsed ALL when administered on a weekly schedule
- 50% complete response rate
  - Of the 10 patients with complete response, 7 became minimal residual disease negative
- Median OS: 7+ months
- No cases of veno-occlusive disease were observed



Antibody drug conjugates (ADCs) use a targeted antibody to deliver a cytotoxin to specific tumor cells – enhancing the anti-tumor activity of an antibody, while reducing the toxicity of the cytotoxin on healthy cells.

Pfizer Oncology

*This is not a Pfizer sponsored study.

Progress of Early Portfolio; Aggressive Management → Smaller, Higher Value Portfolio

Phase I

PF 04449913
SMO inhibitor

PF 05082566
4-1BB

PF 03446962
ALK – 1 mAb

PF 03084014
Gamma secretase inhibitor

PF 04605412
A5/β1mAb

Phase II

PF 04691502 oral
PI3K/mTOR

PF 05212384 IV
PI3K/mTOR

PF 04856884 (CVX-060)
ANG 2

PD 0332991
CDK 4/6 inhibitor

Phase III

Dacomitinib
Pan-HER inhibitor

Inotuzumab Ozogamicin
ADC targeting CD22

FAKi, PAK4i, CVX-241
Discontinued

Tremelimumab
MedImmune/ AstraZeneca

Neratinib
Puma

PARP
Clovis Oncology

PD 0332991 Phase 2 Breast Cancer Trial at IMPAKT



Pfizer Oncology

Key Takeaways

Pfizer Oncology: Dynamic portfolio incorporating a precision medicine approach

RCC	LUNG	HEME	EARLY DEV
Building our RCC portfolio and expertise through launch of Inlyta; Anticipate first line Phase 3 Inlyta data in 2H12	Xalkori launch and uptake driven by increased ALK testing and launches in other geographies; First-in-class pan-HER inhibitor dacomitinib currently enrolling in 2 Phase 3 trials for NSCLC	Bosutinib regulatory reviews for CML in the U.S. and EU continue with decisions expected in 2H12; 2nd Phase 3 trial of inotuzumab to be initiated 2H12	Potential first-in-class position with CDK4,6i and novel PI3K/mToR inhibitor programs

Pfizer Oncology

Q&A

Pfizer Oncology